Natco Pharma

NATCO Pharma on Tuesday announced the launch of generic Pomalidomide capsules indicated for treatment of adult patients with blood and bone marrow cancer in the US market in partnership with Breckenridge Pharmaceutical, Inc. Pomalidomide capsule is a generic version of Pomalyst by Celgene. The product is available in 1mg, 2mg, 3mg, and 4mg strengths and is distributed primarily through specialty pharmacies and clinics, NATCO Pharma said in a regulatory filing. Commenting on the launch, Vice Chairman and CEO Rajeev Nannapaneni said,"...this further strengthens our oncology and specialty portfolio in the US. The launch highlights our commitment to our mission of making specialty medicines accessible to all the patients worldwide." He further said,"We look forward to bringing more such complex and specialty products to the market in the coming years." Breckenridge Pharmaceutical, Inc President and Chief Commercial Officer, Brian Guy said,"Breckenridge's launch of Pomalidomide capsul

Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as rising demand and impending patent expiry fuel intense competition in metabolic and weight-loss therapies

At 01:13 PM on Tuesday; Nifty Pharma index, the top gainer among sectoral indices, was up 0.2 per cent, as compared to 1.1 per cent decline in the Nifty 50.

The buying on the counter came after Natco Pharma received approval from the Central Drugs Standard Control Organisation (CDSCO) for Semaglutide in India

Drug firm Natco Pharma on Tuesday said it has received approval from the US health regulator for a generic cancer medication. The company has received tentative approval for Erdafitinib in strengths of 3 mg, 4mg, and 5 mg, the drug firm said in a regulatory filing. The company's product is a generic version of Janssen Biotech Inc's Balversa. Natco said Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations. As per the industry sales data, Erdafitinib tablets had estimated sales of around USD 60 million in the US for 12 months ending September 2025. Shares of Natco Pharma were trading 3.39 per cent up at Rs 851.45 apiece on BSE.

Strong domestic demand is set to lift pharma revenues by up to 11% in Q3FY26, though pressure from generic Revlimid in the US may limit profit growth

The patent in question is due to lapse in March next year. The court is scheduled to take up Natco's challenge for further hearing in February

Among smallcaps - Natco Pharma, Neuland Laboratories, Inox India, Welspun Living and GE Shipping shares have witnessed the formation of 'Double Bottom' pattern on the technical charts.

Natco Pharma, in a regulatory filing, has informed the exchanges that the credit rating agency ICRA Limited has reaffirmed and assigned credit ratings for Natco Pharma's various debt instruments.

Natco Pharma shares fell 2 per cent as it received seven observations in the Form-483 from the US Food and Drug Administration

Stocks to Watch today, November 24, 2025: From RVNL to HUL, here is a list of stocks that will be on investors' and traders' radar

Natco Pharma Ltd on Friday reported a 23.44 per cent decline in consolidated net profit at Rs 517.9 crore in the second quarter ended September 30, 2025, impacted by higher R&D expenses and one-time employee bonus. The company had posted a consolidated net profit of Rs 676.5 crore in the same quarter of the previous fiscal, Natco Pharma said in a regulatory filing. Consolidated revenue from operations in the second quarter stood at Rs 1,363 crore, as against Rs 1,371.1 crore in the corresponding period last fiscal, it added. Total expenses in the quarter under review stood at Rs 849.3 crore, as compared to Rs 616.7 crore in the same period a year ago, the company said. During the quarter, the company incurred substantial R&D expenses on bioequivalence and one-time employee bonuses, in addition to other business-related provisions, Natco Pharma said. Formulations export revenue was lower at Rs 1,147 crore in the second quarter, compared to Rs 1,211.3 crore in the year-ago ...

The Swiss pharma company has challenged a Delhi High Court ruling that allowed Natco Pharma to sell a generic version of its spinal muscular atrophy drug Risdiplam

The buying on the counter came after the Delhi High Court dismissed an appeal by F. Hoffmann-La Roche AG, removing the last legal hurdle for Natco Pharma to launch a generic version of Risdiplam

Natco Pharma stock was trading at ₹884.5, up 3.2 per cent compared to the previous session's close of ₹857.25 on the NSE

Among stocks, Natco Pharma plunged 37.85%, Ipca Labs 22.43%, Aurobindo Pharma 17.99%, and Sun Pharma 14.30%. Other laggards include Lupin (13.25%), and Dr Reddy's (5.17%).

Here is the complete list of stocks that will remain in focus today as they trade ex-dividend on August 19, along with their key details

Nifty Pharma index declined 1.5 per cent in trade after US President Donald Trump warned to impose a 25 per cent tariff on Indian goods starting August 1

The proposed Rs 2,000 crore deal will give Natco Pharma a strategic foothold in South Africa, with transaction completion expected within four months subject to approvals

Stocks to buy: Analyst pick Sharda Cropchem, Monarch Networth Capital and one more share to buy; Check full details